IL5RA and asthma: Benralizumab is an anti‐eosinophilic, anti‐ IL‐5Rα humanised afucosylated monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve nasal polyp score for individuals with uncontrolled, severe asthma or CRSwNP.97, 100